diethylcarbamazine has been researched along with Adverse Drug Event in 5 studies
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe adverse reactions have been observed in individuals with Loa loa infection treated with either diethylcarbamazine (DEC), the drug of choice for loiasis, or ivermectin (IVM), which is used in mass drug administration programs for control of onchocerciasis and lymphatic filariasis in Africa." | 5.24 | Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection. ( Bopda, J; Fay, MP; Gounoue, R; Herrick, JA; Kamgno, J; Klion, AD; Legrand, F; Makiya, M; Metenou, S; Montavon, C; Nchinda, G; Nguluwe, K; Nutman, TB; Ondigui, BE; Tchana, SM, 2017) |
| " Adverse events (AEs) were monitored actively for two days and passively for five more days." | 3.01 | An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. ( Dwivedi, GP; Jambulingam, P; Krishnamoorthy, K; Kuttiatt, VS; Rahi, M; Raju, HKK; Somani, RK; Srividya, A; Subramanian, S; Suryaprakash, MK; Weil, GJ, 2021) |
| "Lymphatic filariasis has remained endemic in Fiji despite repeated mass drug administration using the well-established and safe combination of diethylcarbamazine and albendazole (DA) since 2002." | 2.94 | The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial. ( Grobler, AC; Hardy, M; Kaldor, JM; Kama, M; King, CL; Robinson, LJ; Romani, L; Samuela, J; Steer, AC; Tuicakau, M; Weil, GJ; Whitfeld, MJ, 2020) |
| " Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels." | 2.82 | Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. ( Baea, M; Fleckenstein, LL; Kazura, JW; King, CL; Lombore, B; Maki, E; Sanuku, N; Satofan, S; Schmidt, MS; Siba, PM; Thomsen, EK; Weil, GJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Hardy, M | 1 |
| Samuela, J | 1 |
| Kama, M | 1 |
| Tuicakau, M | 1 |
| Romani, L | 1 |
| Whitfeld, MJ | 1 |
| King, CL | 2 |
| Weil, GJ | 3 |
| Grobler, AC | 1 |
| Robinson, LJ | 1 |
| Kaldor, JM | 1 |
| Steer, AC | 1 |
| Jambulingam, P | 1 |
| Kuttiatt, VS | 1 |
| Krishnamoorthy, K | 1 |
| Subramanian, S | 1 |
| Srividya, A | 1 |
| Raju, HKK | 1 |
| Rahi, M | 1 |
| Somani, RK | 1 |
| Suryaprakash, MK | 1 |
| Dwivedi, GP | 1 |
| Herrick, JA | 1 |
| Legrand, F | 1 |
| Gounoue, R | 1 |
| Nchinda, G | 1 |
| Montavon, C | 1 |
| Bopda, J | 1 |
| Tchana, SM | 1 |
| Ondigui, BE | 1 |
| Nguluwe, K | 1 |
| Fay, MP | 1 |
| Makiya, M | 1 |
| Metenou, S | 1 |
| Nutman, TB | 1 |
| Kamgno, J | 1 |
| Klion, AD | 1 |
| Thomsen, EK | 1 |
| Sanuku, N | 1 |
| Baea, M | 1 |
| Satofan, S | 1 |
| Maki, E | 1 |
| Lombore, B | 1 |
| Schmidt, MS | 1 |
| Siba, PM | 1 |
| Kazura, JW | 1 |
| Fleckenstein, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection[NCT01593722] | Phase 4 | 155 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa[NCT01975441] | Phase 2 | 182 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis[NCT02899936] | 23,789 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis[NCT04410406] | Phase 3 | 164 participants (Actual) | Interventional | 2020-08-20 | Active, not recruiting | ||
| Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators[NCT03352206] | 20,092 participants (Actual) | Observational | 2017-10-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01593722)
Timeframe: 14 days
| Intervention | participants (Number) |
|---|---|
| Diethylcarbamazine | 3 |
| Ivermectin | 0 |
Symptoms, signs and laboratory abnormalities occurring in the 7 days post-treatment (NCT01593722)
Timeframe: 7 days
| Intervention | events (Number) |
|---|---|
| Diethylcarbamazine | 115 |
| Ivermectin | 103 |
(NCT01593722)
Timeframe: 7 days
| Intervention | percentage of baseline (Geometric Mean) |
|---|---|
| Diethylcarbamazine | 196 |
| Ivermectin | 165 |
Proportion of subjects without signs of infection (NCT01593722)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Diethylcarbamazine | 0 |
| Ivermectin | 1 |
Levels of surface marker expression on eosinophils (NCT01593722)
Timeframe: 3 days
| Intervention | % cells expressing CD69 (Geometric Mean) | |
|---|---|---|
| %CD69 expression on eosinophils at peak | %CD69 expression on eosinophils at baseline | |
| Single Dose DEC | 21.5 | 1.7 |
| Single Dose IVM | 21.5 | 1.5 |
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
4 trials available for diethylcarbamazine and Adverse Drug Event
| Article | Year |
|---|---|
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Antiparasitic Agents; Child; Child, Prescho | 2020 |
An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Diethylcarbamazine; Drug-Related Side Effects and Ad | 2021 |
Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
Topics: Adult; Aged; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; Female; Filaricide | 2017 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
1 other study available for diethylcarbamazine and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |